Lege Artis Medicinae

[Medicine-induced osteonecrosis of the jaw]

VASZILKÓ Mihály, CSÉPLŐ Krisztina, NÉMETH Zsolt, BARABÁS József, UJPÁL Márta

JANUARY 27, 2009

Lege Artis Medicinae - 2009;19(01)

[INTRODUCTION - Bisphosphonates are often used in the treatment of osteoporosis and of certain tumors with bone defects. Thus their rare side effect, necrosis of the jaw becomes more and more frequent. CASE REPORT - Between September 2005 and March 2008 we have treated 40 patients with bisphosphonate induced osteonecrosis in the maxillofacial region at our hospital. From this group, we selected two cases where typical complications emerged. CONCLUSION - Based upon data from the international literature and on our own experiences, we would like to draw attention to the importance of prevention. If symptoms are emerging, referral to a specialized department prepared to the treatment of this condition is recommended.]

COMMENTS

0 comments

Further articles in this publication

Lege Artis Medicinae

[The Adventures of Haydn’s Skull]

GERLINGER Imre

Lege Artis Medicinae

[Cost-effectiveness of self monitoring of blood glucose in patients with non-insulin treated type 2 diabetes]

SIMON Judit, GRAY Alastair, CLARKE Philip, WADE Alisha, NEIL Andrew, FARMER Andrew

Lege Artis Medicinae

[The lost humanness]

FRENKL Róbert

Lege Artis Medicinae

[Effects of pantoprazole on ulcer healing delay associated with NSAID treatment]

NEMESÁNSZKY Elemér

Lege Artis Medicinae

[New possibilities in the management of hepatocellular carcinoma]

DANK Magdolna

[The prognosis of primary hepatocellular carcinoma (HCC) has been poor until recently. Most patients are diagnosed at an advanced stage, with a poor liver function, thus therapeutic possibilities are limited. In high-risk patients, active surveillance and HCC screening is essential for early diagnosis. Experience with systemic chemotherapy has been disappointing with low response rates and high rates of adverse effects. Recently, novel treatment options have emerged, including the use of specific targeted agents, blockers of signaling pathways involved in hepatocarcinogenesis. Sorafenib, an oral multikinase- inhibitor is the first systemic agent to demonstrate survival benefit in advanced hepatocellular cancer. Several new, promising therapeutic options are being tested in clinical trials. The present review gives an overview of evolving diagnostic and therapeutic strategies.]

All articles in the issue

Related contents

Ca&Bone

[Paget’s disease of the bones]

DONÁTH Judit

[The author provides a summary of the current knowledge on Paget’s disease. Recently, the greatest advances have been made in the fields of genetics and therapy.The incidence of the disease is far greater than the number of cases diagnosed. Current research focuses on proving the virus hypothesis of etiology as well as on genetic causes.Various new biochemical markers have become available, but serum alkaline phosphatase is still the most widely used parameter. Radiological studies remain the gold standard for the diagnosis of Paget’s disease. Clinical trials of the most recent bisphosphonates are ongoing.]

Clinical Oncology

[Tyrosine-kinase inhibitors and bisphosphonates in the treatment of metastases from renal cell carcinoma]

EDUARD Vrdoljak, TOMISLAV Omrčen

[Bone metastases (BMs) are common in patients with renal cell carcinoma (RCC) and approximately in 30% of patients with metastatic RCC (mRCC) will develop. Inhibition of vascular endothelial growth factor (VEGF) has been pursued as a therapeutic target in the treatment of metastatic clear cell RCC (mRCC). Tyrosine kinase inhibitors (TKIs), such as sunitinib, pazopanib, sorafenib, and axitinib, became the therapy of choice for patients with mRCC. Apart from the undisputed effi cacy of TKI in treatment of mRCC, the problem of metastatic bone disease still remains. There is evidence that the presence of BMs in m-RCC patients has a signifi cant and clinically-relevant negative impact on survival and potentially on the outcome of VEGF-targeted therapy. Also, common practice in the treatment of such patients is bonedirected therapy with BPs. Recent evidence shows a potentially synergistic effect on effi cacy but also a potential impact on increased toxicity of combining TKIs and BPs. This review highlights the importance of this subject and aims to facilitate further research and optimize the treatment of this important and common group of RCC patients.]

LAM KID

[Osteonecrosis of the jaws: real and unreal scares]

VASZILKÓ Mihály

[Osteonecrosis caused by bisphosphonates has been known for a long time, but it is still not widely known. Some people overestimate the danger caused by this disease, whereas others underrate it. In this paper, we summerise data from the international literature and our experiences concerning 93 patients treated at our clinic. We discuss the already known details of the pathomechanism of this disease, its risk factors, the diagnostic methods, the specific stages of the disease and the treatment approaches. Considering the difficulties of treatment, we can't emphasise enough the importance of prevention, since the development of this complication can be minimised even in patients at risk with dental sanation before the bisphosphonate therapy and/or with further intervention performed with antibiotic preventive therapy. We must also point out the importance of early diagnosis and of directing these patients to the appropriate specialist units.]

Lege Artis Medicinae

[IBANDRONATE IN THE TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS]

LAKATOS Péter

[Postmenopausal osteoporosis affects 7-10% of the population of developed countries. During the past decade, a number of new therapeutical modalities have been made available. Among these, bisphosphonates mean the mainstay of medical treatment. Ibandronate belongs to the amino-bisphosphonate group of these drugs. Amino-bisphosphonates act via the mevalonate metabolic pathway, thus, inhibiting protein prenylation. Several clinical studies have shown a significant reduction in the fracture risk of osteoporotic patients treated with ibandronate. This compound can be administered orally once a month or intravenously once in every 3 months. Longer dosing intervals stimulate patient compliance, and consequently increase efficacy and cost effectiveness.]

Lege Artis Medicinae

[Oral clodronate for the prevention and therapy of bone metastasis of breast cancer]

NAGYKÁLNAI Tamás

[1600 mg/d oral clodronate has been shown to reduce the incidence of skeletal complications significantly in advanced breast cancer cases with lytic bone metastases. Analysis of clinical trials revealed that the adjuvant, prophylactic administration of clodronate possibly decreases the number of non-skeletal metastases and might prolong survival.]